EA201490194A1 - Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака - Google Patents

Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака

Info

Publication number
EA201490194A1
EA201490194A1 EA201490194A EA201490194A EA201490194A1 EA 201490194 A1 EA201490194 A1 EA 201490194A1 EA 201490194 A EA201490194 A EA 201490194A EA 201490194 A EA201490194 A EA 201490194A EA 201490194 A1 EA201490194 A1 EA 201490194A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
cancer treatment
combined therapy
including cdk4
pi3k
Prior art date
Application number
EA201490194A
Other languages
English (en)
Other versions
EA030465B1 (ru
Inventor
Сункиу Ким
Шиванг Доши
Кристи Хаас
Стивен Коватс
Алан Сичжун Хуан
Янь Чэнь
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46513871&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490194(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201490194A1 publication Critical patent/EA201490194A1/ru
Publication of EA030465B1 publication Critical patent/EA030465B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Комбинация ингибитора CDK4/6 и ингибитора PI3 киназы для лечения рака.
EA201490194A 2011-07-01 2012-07-02 Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака EA030465B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161503642P 2011-07-01 2011-07-01
PCT/US2012/045199 WO2013006532A1 (en) 2011-07-01 2012-07-02 Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
EA201490194A1 true EA201490194A1 (ru) 2014-04-30
EA030465B1 EA030465B1 (ru) 2018-08-31

Family

ID=46513871

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490194A EA030465B1 (ru) 2011-07-01 2012-07-02 Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака

Country Status (22)

Country Link
US (2) US9271988B2 (ru)
EP (1) EP2726074B1 (ru)
JP (2) JP5832647B2 (ru)
KR (1) KR20140040770A (ru)
CN (1) CN103635189B (ru)
AU (3) AU2012279117A1 (ru)
BR (1) BR112013033940A2 (ru)
CA (1) CA2840754A1 (ru)
CL (1) CL2013003805A1 (ru)
CO (1) CO6842016A2 (ru)
EA (1) EA030465B1 (ru)
ES (1) ES2676180T3 (ru)
GT (1) GT201300320A (ru)
IL (1) IL229876B (ru)
MA (1) MA35210B1 (ru)
MX (1) MX359406B (ru)
MY (1) MY161237A (ru)
PE (1) PE20141381A1 (ru)
TN (1) TN2013000508A1 (ru)
UA (1) UA114178C2 (ru)
WO (1) WO2013006532A1 (ru)
ZA (1) ZA201309241B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG187425A1 (en) 2008-01-04 2013-02-28 Intellikine Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
PE20141303A1 (es) 2011-01-10 2014-10-01 Infinity Pharmaceuticals Inc Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
PE20141381A1 (es) * 2011-07-01 2014-10-21 Novartis Ag Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
JP2015512416A (ja) * 2012-03-30 2015-04-27 ノバルティス アーゲー 神経芽細胞腫、ユーイング肉腫または横紋筋肉腫の治療に使用するための化合物
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2880448B1 (en) 2012-08-03 2022-06-29 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
EP2742940B1 (en) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
US9527857B2 (en) 2013-03-15 2016-12-27 GI Therapeutics, Inc. HSPC-sparing treatments for RB-positive abnormal cellular proliferation
WO2014144740A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
EP3033086B1 (en) * 2013-08-14 2021-09-22 Novartis AG Combination therapy for the treatment of cancer
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015161285A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
WO2016040858A1 (en) * 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
US9643980B2 (en) 2015-07-02 2017-05-09 Genentech, Inc. Benzoxazepin oxazolidinone compounds and methods of use
RU2730529C2 (ru) 2015-07-02 2020-08-24 Ф. Хоффманн-Ля Рош Аг Соединения бензоксазепиноксазолидинонов и способы применения
CN108348514A (zh) * 2015-08-28 2018-07-31 诺华股份有限公司 含pi3k抑制剂alpelisib和cdk4/6抑制剂ribociclib的药物组合以及其在治疗/预防癌症中的应用
US10690673B2 (en) 2016-03-29 2020-06-23 Mayo Foundation For Medical Education And Research Method of treating cancer metastasis by CDK 4/6 inhibitors
MX2018016227A (es) 2016-06-24 2019-07-08 Infinity Pharmaceuticals Inc Terapias de combinacion.
WO2018017410A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
JP2019536805A (ja) 2016-12-05 2019-12-19 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化学療法計画中の免疫応答の保護
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
BR112020013915A2 (pt) 2018-01-08 2020-12-01 G1 Therapeutics, Inc. regime de dosagem para liberação, e, método para tratar um câncer dependente de replicação de cdk4/6 em um humano
DK3762004T3 (da) * 2018-03-05 2023-11-27 Klinikum Rechts Der Isar Der Technischen Univ Muenchen Behandling af tumorer ved hjælp af en kombination af en oncolytisk adenovirus og en CDK4/6 inhibitor
CN111184863B (zh) * 2018-11-15 2023-06-16 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备***的药物中的用途
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
KR20230007945A (ko) * 2021-07-06 2023-01-13 국립암센터 Cdk4/6 억제제 및 삼환계 항우울제를 포함하는 암의 예방 또는 치료를 위한 약학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
TWI339204B (en) 2002-11-21 2011-03-21 Novartis Vaccines & Diagnostic Small molecule pi 3-kinase inhibitors and methods of their use
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
WO2009098236A1 (en) 2008-02-06 2009-08-13 Novartis Ag Pyrrolo [2, 3-d] pyridines and use thereof as tyrosine kinase inhibitors
BRPI0917791B1 (pt) 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
UA104147C2 (ru) * 2008-09-10 2014-01-10 Новартис Аг Производная пирролидиндикарбоновой кислоты и ее применение в лечении пролиферативных заболеваний
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
ES2699951T3 (es) 2010-10-01 2019-02-13 Novartis Ag Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluorometilpiridin-2-amina, un inhibidor PIK3
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
PE20141381A1 (es) * 2011-07-01 2014-10-21 Novartis Ag Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
JP2016501221A (ja) * 2012-11-28 2016-01-18 ノバルティス アーゲー 併用療法

Also Published As

Publication number Publication date
MX359406B (es) 2018-09-27
ES2676180T3 (es) 2018-07-17
GT201300320A (es) 2016-03-01
US20160136171A1 (en) 2016-05-19
CL2013003805A1 (es) 2014-08-08
US20140107114A1 (en) 2014-04-17
WO2013006532A1 (en) 2013-01-10
BR112013033940A2 (pt) 2017-02-14
JP5832647B2 (ja) 2015-12-16
AU2017232162B2 (en) 2019-03-07
MY161237A (en) 2017-04-14
US9271988B2 (en) 2016-03-01
EP2726074A1 (en) 2014-05-07
CA2840754A1 (en) 2013-01-10
US10010552B2 (en) 2018-07-03
TN2013000508A1 (en) 2015-03-30
CN103635189A (zh) 2014-03-12
UA114178C2 (uk) 2017-05-10
AU2012279117A1 (en) 2014-01-09
EP2726074B1 (en) 2018-04-04
AU2017232162A1 (en) 2017-10-12
EA030465B1 (ru) 2018-08-31
IL229876B (en) 2018-10-31
JP2014518279A (ja) 2014-07-28
MX2013015370A (es) 2014-02-11
PE20141381A1 (es) 2014-10-21
CO6842016A2 (es) 2014-01-20
CN103635189B (zh) 2016-05-04
AU2016202213A1 (en) 2016-05-05
JP2016027043A (ja) 2016-02-18
KR20140040770A (ko) 2014-04-03
MA35210B1 (fr) 2014-06-02
ZA201309241B (en) 2014-08-27

Similar Documents

Publication Publication Date Title
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
CY1121882T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
TWD161529S (zh) 治療燈
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
EA201400178A1 (ru) Лечение рака молочной железы
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
TR201904980T4 (tr) Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
PH12016502353A1 (en) Pharmaceutical composition
TW201613577A (en) Pharmaceutical combinations
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
EA201591024A1 (ru) Димерные соединения
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
PH12015500399A1 (en) Azaindolines
EA201391438A1 (ru) Производные сулиндака, применение и получение указанных производных
MX2013015357A (es) Terapia de combinacion.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ KG TJ TM RU